SOPHiA GENETICS (NASDAQ:SOPH) Insider Manuela Valente Sells 4,240 Shares of Company Stock

Posted by Francis Steltz on Oct 7th, 2026

SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) insider Manuela Valente sold 4,240 shares of the company’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $8.13, for a total transaction of $34,471.20. Following the completion of the transaction, the insider owned 206,210 shares in the company, valued at approximately $1,676,487.30. This trade represents a 2.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SOPHiA GENETICS Price Performance

SOPH traded down $0.23 on Wednesday, reaching $7.15. The company had a trading volume of 432,750 shares, compared to its average volume of 308,157. SOPHiA GENETICS SA has a 52-week low of $3.75 and a 52-week high of $8.98. The company has a market cap of $599.81 million, a price-to-earnings ratio of -6.22 and a beta of 0.95. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The business has a 50 day simple moving average of $7.82 and a 200 day simple moving average of $6.12.

SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The company had revenue of $23.31 million during the quarter, compared to analysts’ expectations of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. As a group, sell-side analysts anticipate that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

More SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

Positive Sentiment: Brokerages reportedly have a consensus price target of $10.00 for SOPHiA GENETICS, suggesting potential upside from recent trading levels if the company meets analyst expectations. SOPHiA GENETICS SA Stock Has Consensus Target Price of $10.00 According to Brokerages
Neutral Sentiment: A comparison article examined SOPHiA GENETICS against Weave Communications, but the item did not identify a specific new company development or change to SOPH’s outlook. Critical Comparison: Weave Communications vs. SOPHiA GENETICS
Negative Sentiment: Company insiders collectively sold approximately 82,298 shares worth $668,827, including sales by Chairman Jurgi Camblong, CEO Ross Muken, CFO George Cardoza, CTO Abhimanyu Verma and other executives. The transactions reduced their individual holdings by roughly 0.15% to 3.55%, creating near-term selling pressure and potentially weighing on investor sentiment. However, all reported sales were pre-arranged and explicitly made to satisfy tax obligations rather than indicating discretionary selling. SEC insider transaction filing

Institutional Investors Weigh In On SOPHiA GENETICS

A number of institutional investors have recently made changes to their positions in SOPH. AWM Investment Company Inc. bought a new position in shares of SOPHiA GENETICS during the 2nd quarter valued at $9,809,000. Hodges Capital Management Inc. bought a new position in SOPHiA GENETICS during the 1st quarter worth approximately $2,157,000. Sei Investments Co. bought a new stake in SOPHiA GENETICS in the first quarter valued at approximately $1,772,000. Maven Securities LTD purchased a new stake in shares of SOPHiA GENETICS during the second quarter valued at approximately $866,000. Finally, Hennion & Walsh Asset Management Inc. bought a new position in shares of SOPHiA GENETICS in the second quarter worth approximately $567,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Wall Street Analyst Weigh In

SOPH has been the topic of a number of research analyst reports. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. BTIG Research lifted their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. HC Wainwright upped their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $10.00.

View Our Latest Stock Analysis on SOPH

SOPHiA GENETICS Company Profile

(Get Free Report)

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.